Wacker Chemie

A precipitous step deeper into the CDMO business

23/11/20 -"Wacker's Biosolutions business has become a partner of choice for German mRNA player CureVac. Currently, the technology transfer for the production of CureVac's COVID-19 vaccine candidate is being ..."

PDF page sample
Pages
49
Language
English
Published on
23/11/20
Download
You may also be interested by these reports :
12/11/25
1Q25/26: Sales lower but EBITDA better than expected by us as well as by the market – FY25/26E guidance confirmed
11/11/25
K+S reported mixed Q3 2025 results, with sales supported by strong pricing and EBITDA benefiting from a low base, although sales missed expectations. ...
10/11/25
Solvay remained under pressure in Q3 2025 amid persistent macroeconomic headwinds. Chinese overcapacity continued to weigh on soda ash sales, though ...
07/11/25
Arkema’s Q3 2025 results were a mixed bag. Investor sentiment is likely supported by guidance matching consensus and management’s optimistic ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO